Deep knowledge on 
 small-molecule drugs and 
 the 110,000 global patents 
 covering them 

Free Patent Expiration Alerts


Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

JAKAFI Drug Profile

« Back to Dashboard
Jakafi is a drug marketed by Incyte Corp and is included in one NDA. It is available from one supplier. There are six patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and one patent family members in thirty-eight countries.

The generic ingredient in JAKAFI is ruxolitinib phosphate. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the ruxolitinib phosphate profile page.

Summary for Tradename: JAKAFI

Patents:6
Applicants:1
NDAs:1
Suppliers / Packagers: see list1

Pharmacology for Tradename: JAKAFI

Drug ClassKinase Inhibitor
Mechanism of ActionProtein Kinase Inhibitors

Clinical Trials for: JAKAFI

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Incyte Corp
JAKAFI
ruxolitinib phosphate
TABLET;ORAL202192-003Nov 16, 2011RXNo9,079,912<disabled> <disabled>
Incyte Corp
JAKAFI
ruxolitinib phosphate
TABLET;ORAL202192-004Nov 16, 2011RXNo<disabled><disabled>
Incyte Corp
JAKAFI
ruxolitinib phosphate
TABLET;ORAL202192-005Nov 16, 2011RXYes8,415,362<disabled>YY <disabled>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: JAKAFI

Drugname Dosage Strength RLD Submissiondate
ruxolitinibTablets5 mg, 10 mg, 15 mg, 20 mg, and 25 mgJakafi12/17/2015

Non-Orange Book Patents for Tradename: JAKAFI

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,530,485Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors<disabled in preview>
8,933,086Heteroaryl substituted pyrrolo[2,3-B]pyridines and pyrrolo[2,3-B]pyrimidines as Janus kinase inhibitors<disabled in preview>
9,206,187Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as Janus kinase<disabled in preview>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: JAKAFI

Country Document Number Estimated Expiration
Japan5475653<disabled in preview>
Eurasian Patent Organization019784<disabled in preview>
Japan2010529209<disabled in preview>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: JAKAFI

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0130003 00072Estonia<disabled>PRODUCT NAME: RUKSOLITINIIB;REG NO/DATE: K(2012)6018 LOPLIK 23.08.2012
2013 00005Denmark<disabled>PRODUCT NAME: RUXOLITINIB, ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, HERUNDER RUXOLITINIB PHOSFAT; REG. NO/DATE: EU/1/12/773/001-003 20120823
137Luxembourg<disabled>PRODUCT NAME: RUXOLITINIB,OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2016 thinkBiotech LLC
ISSN: 2162-2639

Connect with Social Media:

`abc